Avallano, an AI-enabled clinical research company, announced the appointment of Michael A. Ibara, PharmD., as Chief Strategy Officer (CSO). Dr. Ibara will lead the company's global strategic initiatives to transform the clinical trial sector with leading-edge technology solutions.

Prior to joining Avallano Dr. Ibara served as Chief Data Officer at Elligo Health Solutions.

Dr. Ibara will lead the launch of Avallano's generative AI technologies, aimed at enhancing clinical research by addressing the challenges faced by patients, sites, and sponsors in executing clinical trials.

Avallano’s solutions include personalized patient chat services, AI-driven medical information processing, founded on a market-leading approach to global privacy and patient empowerment. He’ll guide the company in balancing regulatory compliance requirements with the capabilities of explainable AI. Explainable AI helps users understand complex AI models and determine what factors influence decision-making.

"Michael’s extensive experience in the biopharmaceutical industry and his innovative approach to data and clinical operations make him the perfect fit for Avallano," said Paul Della Maggiora, Co-Founder and CEO. "We have already benefited from Michael’s strategic vision as an advisor and confident that his leadership will help us achieve our ambitious goals and continue to provide exceptional service to our clients."

Dr. Ibara holds a Pharm.D. from the University of Michigan and a Fellowship from the University of North Carolina and Burroughs Wellcome Co.